Covid-19: Road Map

Debate between Baroness Evans of Bowes Park and Lord Moylan

Tuesday 23rd February 2021 Lords Chamber

[Baroness Evans of Bowes Park (Con)]

My noble friend is right, but we should recognise that hospitals and staff have gone to extraordinary lengths to deliver non-Covid care and treatment, from online consultations to chemo buses and Covid-free surgical hubs. We have seen the benefit of these, with, for instance, almost 390,000 people being treated for cancer between March and November last year. But he is right: waiting times have increased. We have allocated £1 billion to help the NHS recover elective care backlogs. This will be enough funding to enable hospitals to carry out up to 1 million extra checks, scans and additional operations and procedures. We are well aware of the issue he raises. I thank everyone in the NHS for all the work they are doing, but we understand that more work needs to be done.

[Lord Moylan (Con)]

My Lords, as various noble Lords have said, the Government’s plan accepts that Covid is going to remain endemic in the population for many years to come. In fact, the Prime Minister stated in emphatic and, in my view, realistic terms that there is no credible path to a zero-Covid Britain. In that light, does my noble friend agree that the right response is for the UK to redouble its already world-beating efforts to develop and discover new and effective cures and treatments for serious Covid cases?

[Baroness Evans of Bowes Park (Con)]

I entirely agree with my noble friend. That is absolutely right and we have been at the forefront of that. He may be interested to know that we have also established a new partnership with vaccine manufacturer CureVac, which means that we are ready to build on our world-leading genomics expertise to develop new vaccines quickly if new variants appear. We have already placed an initial order for 50 million CureVac doses, in addition to the portfolio of more than 400 million doses that we have already secured. We believe that this will help ensure the ability rapidly to develop and deploy vaccines against any new variant or similar new diseases in the future.